Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy

Background Salvage radical prostatectomy (sRP) is an important treatment option for patients with recurrent prostate cancer (PCa) after radiotherapy (RT) or focal therapy (FT).

However, health-related quality of life (HRQOL) after sRP depending on the primary treatment is understudied.

Methods Patients who underwent Salvage RP for recurrent PCa were analyzed.

The primary outcome of this study was HRQOL assessed by the quality-of-life questionnaire (QLQ)-C30 and its prostate specific QLQ-PR25 add-on.

Secondary outcomes were functional outcome parameters (erectile function, continence) and biochemical recurrence-free survival (BRFS).

Statistical analyses employed the chi-square test, Mann–Whitney U test, and Kaplan–Meier method, with a p value < 0.05 denoting significance.

Results 37 patients with RT as primary treatment (RT-sRP) and 22 patients with focal therapy prior sRP (FT-sRP) were analyzed.

Mean global health score was not significantly different preoperatively (71.9 vs. 67.3, p  = 0.89) as well as after a median of 32 months follow-up (54.9 vs. 50.6, p  = 0.63) with impaired HRQOL after sRP in both groups.

Baseline erectile dysfunction was more prevalent in the RT-sRP group (mean IIEF-5: 5.0) than in the FT-sRP group (mean IIEF-5: 8.5, p  = 0.037).

No differences were observed at follow-up for erectile function (IIEF-5-Score: 0.5 vs 2.5, p  = 0.199) and continence (continence rate: 48.4% vs 52.9% ( p  = 0.763) between the RT-sRP and FT-sRP group.

5-year-BRFS was 60% (RT-sRP) and 68% (FT-sRP, p  = 0.849).

Conclusions sRP impacts HRQOL in patients with PCa after RT and FT with no significant differences.

Comparison with HRQOL and BRFS of treatment alternatives is paramount to counsel patients for appropriate treatments.